The antimetastatic effect of aprepitant in osteosarcoma is probably attributed to its ability to modulate the transcriptional regulator nuclear factor kappa B (NF-κB) and, subsequently, its target genes, including MMP-2, MMP-9, and VEGF-A [13] (Figure 1). Here, MMP9 is linked to osteosarcoma.